PROGRAM

All sessions will be held at the Hyatt Regency Jersey City (Manhattan Ballroom, 9th Floor).

Review Speaker Bios Here

Sunday, September 15

5:00–7:00pm Registration

Monday, September 16

8:00am–5:30pmRegistration
8:00–9:00amContinental Breakfast
9:00–9:20Welcome & Introductory Notes
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
9:20–9:50KEYNOTE: Extracellular Vesicle Biomarkers Revolutionize Preclinical Diagnosis of AD and Assessment of Treatment Responses in Clinical Trials
Dimitrios Kapogiannis, MD—National Institutes of Health
9:50-10:00Q&A
Session I: SMALL MOLECULE APPROACHES FOR ALZHEIMER’S DISEASE
Chair: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:00–10:05Session Overview: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:05–10:25Q134R: Novel Small Chemical Compound with NFAT Inhibitory Properties Ameliorates Synaptic Deficits in a Mouse Model of Alzheimer's Disease
Christopher Norris, PhD—University of Kentucky
10:25–10:35Q&A
10:35–10:55 Inhibiting Ryanodine Receptors, an ER Calcium Channel, to Prevent Synaptic Pathology and Protein Mishandling
Grace (Beth) Stutzmann, PhD—Chicago Medical School/NeuroLucent, Inc
10:55–11:05Q&A
11:05–11:35EXHIBITOR SESSION BREAK
11:35–11:55Design and Exploration of NLRP3 Inhibitors for Neurodegenerative Disorders
Shijun Zhang, PhD—Virginia Commonwealth University
11:55am–12:05pmQ&A
12:05–12:25Pharmacological Inhibition of EP2 Receptors Suppress Neuroinflammation in the Female 5xFAD Mice, but not in the Male 5xFAD Mice
Thota Ganesh, PhD—Emory University
12:25–12:35Q&A
12:35–1:05POSTER SESSION
1:05–2:00
LUNCH
Session II: NOVEL APPROACHES FOR FRONTOTEMPORAL DEMENTIA
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:00–2:05Session Overview: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:05–2:25TDP-43 Proteinopathies: Challenges and Opportunities for a Pathology-specific Biofluid Test
Mari DeMarco, PhD—University of British Columbia
2:25–2:35Q&A
2:35–2:55Human Microglial and Neuronal Models of Frontotemporal Dementia and Strategies to Rescue Progranulin Haploinsufficiency
Steven Finkbeiner, MD, PhD—Gladstone Institutes/University of California, San Francisco
2:55–3:05Q&A
3:05–3:25Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: the Neurofilament Light Surveillance Project (NSP)
Rodney Pearlman, PhD—The Bluefield Project to Cure FTD
3:25–3:35Q&A
3:35–3:55Non-invasive Brain Stimulation to Restore Cortical Connectivity in FTD
Alberto Benussi, MD—University of Brescia
3:55–4:05Q&A
4:05–4:35EXHIBITOR SESSION BREAK
4:35–5:20 EMERGING CONCEPTS: DATA BLITZ
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation

Neuron-targeted Caveolin-1 Preserves Hippocampal Neuroplasticity and Memory in AD Mice
Young Investigator #1: Shanshan Wang, MD, PhD—University of California, San Diego

Treatment with AUY954, a Selective Sphingosine-1-phosphate Receptor 1 Agonist, Reduces Early Development of AI Pathology and Neuroinflammation in a Mouse Model of Alzheimer's Disease
Young Investigator #2: Christina Tognoni, PhD—Boston University/VA Boston Healthcare System

Memory Impairments and Synaptic Failure in Tg19959 AD Model Mice Are Alleviated by Eef2k Inhibitor A-484954
Young Investigator #3: Nicole Kasica, PhD (cand.)—Wake Forest University
5:20–5:30Closing Remarks and Announcement of Young Investigator Scholarships
Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
5:30–7:00NETWORKING RECEPTION

Tuesday, September 17

7:30–8:20amContinental Breakfast
8:20–8:50SPECIAL SESSION: NIA's Alzheimer’s and Related Dementias Translational Research Funding Opportunities
Zane Martin, PhD—National Institute on Aging
8:50–9:20 KEYNOTE: The Use of Platform Trials in CNS Disorders
Sabrina Paganoni, MD, PhD—Massachusetts General Hospital/Harvard University
9:20-9:30Q&A
Session III: CLINICAL TRIALS IN ALZHEIMER’S DISEASE
Chair: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:30–9:35 Session Overview: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:35–9:55Rasagiline Rescue (R2): A Double-Blind Placebo Controlled Trial for Mild to Moderate Alzheimer’s Disease
Jeffrey Cummings, MD, ScD—Cleveland Clinic
9:55–10:05Q&A
10:05–10:25Clinical Biomarker Evidence for Target Engagement, Reduction of Synaptic Damage and Disease Modification in Alzheimer’s Patients Treated with CT1812 (ElaytaTM)
Susan Catalano, PhD—Cognition Therapeutics
10:25–10:35Q&A
10:35–11:05EXHIBITOR SESSION BREAK
11:05–11:25Vafidemstat: The First Epigenetic Approach in Alzheimer's Disease
Roger Bullock, MBBS—Oryzon
11:25–11:35Q&A
11:35–11:55Vascular Approaches for Alzheimer’s Treatment
Ihab Hajjar, MD—Emory Health Care
11:55am–12:05pmQ&A
12:05–12:35POSTER SESSION
12:35–1:15LUNCH
Session IV: NOVEL BIOMARKER APPROACHES
Chair: Nicole Bjorklund, PhD—Alzheimer’s Drug Discovery Foundation
1:15–1:20Session Overview: Nicole Bjorklund, PhD—Alzheimer’s Drug Discovery Foundation
1:20 –1:40FDG PET, Tau PET, and MR Imaging Biomarkers in Alzheimer’s Disease Therapeutic Trials
Dawn Matthews, MS, MBA—ADMdx
1:40–1:50Q&A
1:50–2:10Resilience Biomarker NPTX2 and AD Progression
Paul Worley, MD—Johns Hopkins University
2:10–2:20Q&A
2:20–2:40The Utility of cFLIP and MCL I and their Regulatory MicroRNAs as Novel Biomarkers of Alzheimer's Disease
Esmerina Tili, PhD—OSU/Gnome Diagnostics, LLC
2:40–2:50Q&A
2:50-3:10Ocular Approaches for Alzheimer’s Diagnosis
Swati More, PhD—University of Minnesota
3:10-3:20Q&A
3:20-3:30pmClosing Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation